Please login to the form below

Not currently logged in
Email:
Password:

European firms face compliance challenges

The European Trends in Aggregate Spend, Transparency and Disclosure report reveals life science concerns over the compliance landscape

Results of a survey into European trends in aggregate spend, transparency and disclosure, issued on November 16 by Cegedim Relationship Management, reveal that 93 per cent of respondents are concerned that regulatory compliance will be a major challenge to the life sciences industry in Europe over the next three years, and impact industry image.

Survey respondents, comprising a representative sample of European executives from compliance, legal, marketing and sales departments within life science organisations, cited data identification, consistency and quality as major challenges to project implementation and compliance governance processes. 

While the European compliance function has traditionally focused on high-level governance design, the survey predicts changes to the evolving compliance landscape will have an effect on daily processes. For instance, the research predicts a 10 per cent drop in the use of Excel to monitor expenditure, and an increased dependency on third party solutions to meet compliance requirements.

Regulatory compliance is top of the agenda across Europe, but is particularly so in the UK, where the industry body - the Association of the British Pharmaceutical Industry (ABPI)  – is implementing transparency reforms to its Code and amendments to the Bribery Act will be legislated in April 2010.

17th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics